Meeting
2017 ASCO Annual Meeting
Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).
Authors
Noah M. Hahn
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Noah M. Hahn , Thomas Powles , Christophe Massard , Hendrik-Tobias Arkenau , Terence W. Friedlander , Christopher J. Hoimes , Jae-Lyun Lee , Michael Ong , Srikala S. Sridhar , Nicholas J. Vogelzang , Mayer N. Fishman , Jingsong Zhang , Sandy Srinivas , Jigar Parikh , Joyce Antal , Xiaoping Jin , Yong Ben , Ashok Kumar Gupta , Peter H. O'Donnell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT01693562
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4525)
DOI
10.1200/JCO.2017.35.15_suppl.4525
Abstract #
4525
Poster Bd #
203
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.
First Author: Matthew D. Hellmann
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
First Author: Robert L. Ferris
Poster
2023 ASCO Annual Meeting
The metabolic activity assessed by 18F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab.
First Author: Jeesun Yoon
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse